[go: up one dir, main page]

EP3302464A4 - USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN - Google Patents

USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN Download PDF

Info

Publication number
EP3302464A4
EP3302464A4 EP16799004.3A EP16799004A EP3302464A4 EP 3302464 A4 EP3302464 A4 EP 3302464A4 EP 16799004 A EP16799004 A EP 16799004A EP 3302464 A4 EP3302464 A4 EP 3302464A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
inflammation
treatment
eye pain
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16799004.3A
Other languages
German (de)
French (fr)
Other versions
EP3302464A1 (en
Inventor
Mary Lynch
Melanie KELLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panag Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/722,991 external-priority patent/US9549906B2/en
Application filed by Individual filed Critical Individual
Publication of EP3302464A1 publication Critical patent/EP3302464A1/en
Publication of EP3302464A4 publication Critical patent/EP3302464A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16799004.3A 2015-05-27 2016-05-27 USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN Withdrawn EP3302464A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/722,991 US9549906B2 (en) 2013-11-20 2015-05-27 Compositions and methods for treatment of ocular inflammation and/or pain
PCT/CA2016/050603 WO2016187722A1 (en) 2015-05-27 2016-05-27 Use of cannabinoids in the treatment of ocular inflammation and/or pain

Publications (2)

Publication Number Publication Date
EP3302464A1 EP3302464A1 (en) 2018-04-11
EP3302464A4 true EP3302464A4 (en) 2019-01-23

Family

ID=57395729

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16799004.3A Withdrawn EP3302464A4 (en) 2015-05-27 2016-05-27 USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN

Country Status (2)

Country Link
EP (1) EP3302464A4 (en)
WO (1) WO2016187722A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018325465A1 (en) * 2017-09-02 2020-05-28 Scientific Holdings, Llc Tetrahydrocannabinol modulators
EP3643303A1 (en) * 2018-10-22 2020-04-29 InnovativeHealth Group SL Compounds for use in the treatment or prevention of fibrotic diseases; pharmaceutical, cosmetic compositions and uses thereof
CA3171726C (en) * 2020-08-21 2025-05-13 Altus Formulation Inc Dual analgesic/anti-inflammatory compositions, combinations, and methods of use thereof
CN113491681A (en) * 2021-08-11 2021-10-12 无锡诺平医药科技有限公司 Application of cannabinoid molecule CBG in preparation of inflammatory pain medicines and medicinal preparation
WO2025210386A1 (en) * 2024-04-01 2025-10-09 Vicadia Lda Pharmaceutical compositions for staining membranes and other biological structures using a natural or synthetic cbd-based vital dye isolated and/or associated with other dyes for vitreoretinal surgery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052013A1 (en) * 2005-11-01 2007-05-10 Gw Pharma Limited A combination of cannabinoids for the treatment of peripheral neurophatic pain
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2014100231A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011514A (en) * 2009-04-28 2011-11-18 Alltranz Inc CANABIDIOL FORMULATIONS AND METHODS TO USE THEM.
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052013A1 (en) * 2005-11-01 2007-05-10 Gw Pharma Limited A combination of cannabinoids for the treatment of peripheral neurophatic pain
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2014100231A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FELDER C C ET AL: "COMPARISON OF THE PHARMACOLOGY AND SIGNAL TRANSDUCTION OF THE HUMAN CANNABINOID CB1 AND CB2 RECEPTORS", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 48, no. 3, 1 January 1995 (1995-01-01), pages 443 - 450, XP009026037, ISSN: 0026-895X *
FRIDE E ET AL: "(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 506, no. 2, 15 December 2004 (2004-12-15), pages 179 - 188, XP004664996, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2004.10.049 *
J T TOGURI ET AL: "Anti-inflammatory effects of cannabinoid CB 2 receptor activation in endotoxin-induced uveitis", BRITISH JOURNAL OF PHARMACOLOGY, vol. 171, no. 6, 1 March 2014 (2014-03-01), UK, pages 1448 - 1461, XP055345492, ISSN: 0007-1188, DOI: 10.1111/bph.12545 *
See also references of WO2016187722A1 *

Also Published As

Publication number Publication date
WO2016187722A1 (en) 2016-12-01
EP3302464A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
EP3858977A4 (en) STRAIN FOR THE PREVENTION AND TREATMENT OF METABOLIC DISEASES AND USE IN RELATION
EP3370748A4 (en) THERAPEUTIC MICROBIOTE FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
MA47688A (en) USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY
MA45481A (en) USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
EP3337465A4 (en) COMPOSITIONS AND METHODS OF USE IN ASSOCIATION FOR THE TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASES
MA50790A (en) DOSAGE OF VIDOFLUDIMUS FOR USE IN THE PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY AND / OR AUTOIMMUNE DISEASES
EP2958580A4 (en) INHIBITION OF SEMA3A IN THE PREVENTION AND TREATMENT OF OCULAR HYPERPERMEABILITY
PT3681857T (en) FLUOROPHENIL-BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCEMIA
EP3735970C0 (en) CÉBRANOPADOL FOR THE TREATMENT OF PAIN IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION AND/OR IMPAIRED RENAL FUNCTION
FR3032353B1 (en) PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN
EP3639833A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO FAT AND / OR INFLAMMATION
EP3512517A4 (en) USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
EP3576738A4 (en) USE OF GABOXADOL IN THE TREATMENT OF TINNASES
EP2854910A4 (en) CERAMIDE LEVELS IN THE TREATMENT AND PREVENTION OF INFECTIONS
EP3302464A4 (en) USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN
MA44762A (en) SEMAGLUTIDE USED IN THE TREATMENT OF CARDIOVASCULAR DISEASES
FR2999428B1 (en) CHITINE OR CHIENE DERIVATIVES FOR USE IN THE PREVENTION AND / OR TREATMENT OF PARASITOSES
EP2969002A4 (en) USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY
MA47450A (en) SULFINYLPYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER
EP3397063A4 (en) USE OF MICROBULLES AND NANOBULLES IN THE TREATMENT OF LIQUID
EP3426307A4 (en) USE OF DREADD FOR NEURONAL MODULATION IN THE TREATMENT OF NEURONAL DISEASES
EP2969001A4 (en) USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF ANAPHYLAXIS
HUE058969T2 (en) Preparations used in the prevention and/or treatment of osteoarticular inflammation and pain and cartilage damage
EP3395341A4 (en) COMPOSITION FOR THE TREATMENT OF NEUROMITRIC DISEASES AND USE THEREOF
EP2906570A4 (en) USE OF SPHINGOID LENGTH CHAINS AND THEIR ANALOGUES IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20181214BHEP

Ipc: C07D 311/80 20060101ALI20181214BHEP

Ipc: A61P 27/02 20060101ALI20181214BHEP

Ipc: A61K 31/05 20060101ALI20181214BHEP

Ipc: A61K 31/352 20060101AFI20181214BHEP

Ipc: A61K 45/06 20060101ALI20181214BHEP

Ipc: A61P 25/02 20060101ALI20181214BHEP

Ipc: C07C 39/23 20060101ALI20181214BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANAG PHARMA INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KELLY, MELANIE

Inventor name: LYNCH, MARY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241203